MK-677 (Ibutamoren): Is It Really a Peptide?

MK-677 shows up on almost every "best peptides" list. It is usually sold as a capsule or liquid, which already hints at something different. This post explains what MK-677 actually is, how it works, what research found, and why it is not an approved medicine.

Key takeaways

• MK-677 is not a peptide. It is a small, non-peptide molecule that is taken by mouth.
• It acts on the ghrelin receptor, the same target as GHRPs like ipamorelin, so it raises growth hormone (GH) and IGF-1 and increases appetite.
• It is not FDA-approved for any use.
• FDA has flagged it for a possible heart failure signal. Higher blood sugar and lower insulin sensitivity are the most consistent side effects in studies.
• It is banned at all times in sport under the 2026 WADA Prohibited List.

So, is it a peptide?

A peptide is a short chain of amino acids linked together. Insulin, semaglutide and ipamorelin are peptides. Peptides are usually broken down in the gut, which is why most of them are injected.

MK-677, also called ibutamoren, is not built from amino acids. It is a small organic molecule designed by a drug company in the 1990s to copy what GHRPs do, but in a pill. That is why it works by mouth.

It ends up on peptide lists because of what it does, not what it is. It acts on the growth hormone secretagogue receptor, the same receptor that ghrelin and GHRP peptides use. Our post on peptides vs. proteins vs. amino acids explains the building blocks if you want a refresher.

How it works

When MK-677 binds the ghrelin receptor, the pituitary releases more GH, and the liver then makes more IGF-1. Because ghrelin is a hunger hormone, MK-677 also tends to increase appetite. It lasts long enough in the body that studies used it once a day. For more on how this class works, see our beginner's guide to GH secretagogues.

What the research shows

MK-677 was studied by its developer and academic groups in the 1990s and 2000s. According to a 2018 review in Sexual Medicine Reviews:

• It reliably raised GH and IGF-1 in study participants.
• Some studies found increases in fat-free mass and changes in markers of bone turnover.
• In a trial in older adults recovering from hip fracture, it produced small functional gains that the review authors did not consider meaningful.
• Most trials were small and short, and none were designed to measure long-term outcomes like cancer or mortality.

In plain terms: MK-677 changes hormone levels and may shift body composition a bit. It has not been shown to make people stronger, healthier or longer-lived in a meaningful way.

Safety concerns

Heart failure signal

The hip fracture trial mentioned above was stopped early partly over heart failure concerns. In that trial, congestive heart failure occurred in about 6.5% of people taking ibutamoren versus 1.7% on placebo, though the review notes that higher baseline blood pressure may have played a role. FDA cites this trial when it lists ibutamoren mesylate as a compounding substance that may present significant safety risks, noting the "potential for congestive heart failure in certain patients."

Blood sugar

The 2018 review called higher blood sugar the main concern with this class. Several MK-677 trials saw higher fasting glucose, higher A1c and lower insulin sensitivity. For anyone with prediabetes or diabetes, or anyone using a GLP-1 for blood sugar or weight, that works in the opposite direction.

Other reported effects

• Increased appetite and weight gain
• Fluid retention and swelling
• Muscle or joint pain
• Temporary rises in cortisol and prolactin
• A published report has described liver injury (hepatotoxicity) linked to MK-677 use

Unknown long-term risks

GH and IGF-1 promote cell growth. The review authors stated that no safety data on cancer or mortality exist for GH secretagogues and called for long-term studies.

Regulatory status

• FDA: Not approved for any use. FDA lists ibutamoren mesylate in Category 2 for both 503A and 503B compounding, meaning it raises significant safety concerns.
• Supplements: MK-677 is sometimes sold as a "supplement" or "research chemical." It is not a legal dietary ingredient for that purpose, and products sold this way are not checked for purity or dose. Our post on research-use-only peptides explains why that matters.
• Sport: The 2026 WADA Prohibited List names ibutamoren (MK-677) as a prohibited GH secretagogue.

Who should be especially careful

Anyone with diabetes or prediabetes, heart failure or heart disease, high blood pressure, a history of cancer, or who is pregnant or breastfeeding should be especially careful. If you are taking a GLP-1 or diabetes medication, the blood sugar effects matter even more. Talk to a licensed provider before taking anything that affects GH. You can track labs and symptoms you discuss with them in the PepSteady app.

The bottom line

MK-677 is a pill, not a peptide. It works through the ghrelin receptor to raise GH and appetite. It is not FDA-approved, it can push blood sugar up, and a trial was stopped early over a possible heart failure signal. The "easy oral peptide" label hides real unknowns.

Sources

• Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018
• FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
• Hepatotoxicity induced by MK-677 (case report), PubMed
• World Anti-Doping Agency: The Prohibited List (2026)

Frequently asked questions